Form 4: PAHC Grants Exec. VP 3,964 Restricted Stock Units

Phibro Animal Health Corp. granted 3,964 restricted stock units to Daniel M. Bendheim, Executive VP of Corporate Strategy, vesting over three years.

Summary

• Daniel M. Bendheim, Director and Executive Vice President, Corporate Strategy, of Phibro Animal Health Corp. (PAHC), was granted 3,964 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Class A Common Stock.
• The RSUs were acquired on August 15, 2025, at a price of $0 per unit.
• The RSUs will vest in substantially equal installments on each of the first three anniversaries of August 1, 2025.
• Vesting is contingent upon Mr. Bendheim's continued employment through the applicable vesting dates.
• Following this transaction, Mr. Bendheim directly beneficially owns 3,964 RSUs.
• Mr. Bendheim also executed a Power of Attorney on August 15, 2025, appointing Judith Weinstein and Henry Ko as attorneys-in-fact for Section 16 reporting obligations.

Sentiment

Score: 7

Explanation: The filing reports a standard executive compensation grant, which is a neutral to slightly positive event as it aligns executive interests with shareholders and promotes retention. There are no negative financial implications or red flags.

Positives

• Granting of RSUs aligns management's interests with long-term shareholder value through equity ownership.
• The vesting schedule over three years encourages retention of key executive talent.
• The Power of Attorney streamlines compliance with SEC reporting requirements for insider transactions.

Risks

• The vesting of the granted RSUs is subject to Daniel M. Bendheim's continued employment through the applicable vesting dates, meaning the full benefit is contingent on his ongoing tenure.

Future Outlook

The vesting schedule for the granted Restricted Stock Units indicates a commitment to retaining Daniel M. Bendheim's services for at least the next three years, aligning his incentives with the company's long-term performance.

Industry Context

This RSU grant is a standard form of executive compensation in publicly traded companies across various industries, including animal health. It aims to incentivize long-term performance and retention of key personnel, a common practice to align executive interests with shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as part of executive compensation is a widely adopted practice across industries, including the animal health sector.
• Companies like Zoetis Inc. (ZTS) and Elanco Animal Health Incorporated (ELAN) also utilize equity-based incentives, often including RSUs, to compensate and retain their executives.
• The vesting period of three years is typical for such grants, providing a balance between immediate reward and long-term commitment.
• The specific number of units granted would typically be benchmarked against peer companies' compensation structures, considering the executive's role and the company's size and performance, though specific comparable figures are not provided.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with long-term company performance and retention of key talent.
• Employees: No direct impact on general employees, but it signals the company's approach to executive incentives.

Next Steps

• The RSUs will vest in substantially equal installments on the first three anniversaries of August 1, 2025.
• Daniel M. Bendheim's continued employment is required for vesting.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation grant of Restricted Stock Units, which is a standard practice to align management incentives with long-term shareholder value and promote executive retention. It does not contain information that would fundamentally alter the investment thesis for Phibro Animal Health Corp. (PAHC), nor does it reveal any significant positive or negative operational or financial news. Therefore, an investor would likely maintain their current position based solely on this filing.

Keywords

Phibro Animal Health Corp, PAHC, Restricted Stock Units, RSU, Equity Compensation, Executive Compensation, Insider Transaction, Form 4, Daniel M. Bendheim, Corporate Governance